Poor
Needs Revision
Patient Risk:
Low
Summary
Only the identification of Keytruda as pembrolizumab is supported by the supplied FDA label. The remaining claims concern European patents, exclusivity, expiry dates, litigation, and market entry, none of which are addressed in the label.
Category Scores
Accurate Statements
Keytruda is pembrolizumab.
Section 11 identifies KEYTRUDA (pembrolizumab) and describes pembrolizumab as the active monoclonal antibody.
Unsupported Statements
Keytruda has multiple layers of intellectual-property coverage in Europe.
The supplied label does not address intellectual-property coverage or European patents.
Certain Keytruda patents or exclusivity periods in Europe have been publicly associated with expiry dates in the 2028–2029 period.
The label contains no patent, exclusivity, jurisdiction, or expiry-date information.
The exact Keytruda expiry year can vary by patent family and jurisdiction.
The label does not discuss patent families, jurisdictions, or expiry dates.
Different patents covering Keytruda can expire in different years.
The label contains no patent-expiry information.
Keytruda’s intellectual-property coverage may include different patent families.
The label does not address intellectual property or patent families.
Keytruda’s intellectual-property coverage may include separate claims tied to specific methods, formulations, or indications.
Although the label describes the product formulation, it does not discuss patent claims or intellectual-property coverage.
One set of Keytruda claims may have an expiry date in 2028 while another may have an expiry date in 2029.
The label contains no information about patent claims or expiry dates.
Patent expiry is not the only factor determining when competitors can enter the market for Keytruda.
The label does not discuss competitor entry, patents, or market exclusivity.
Other active patents covering Keytruda or its indications can delay competitor launch after a patent expires.
The label contains no information about patents, market entry, or competitor launches.
Regulatory or market exclusivities can delay competitor launch after a Keytruda patent expires.
The label does not address regulatory exclusivity, market exclusivity, or competitor launch timing.
Ongoing litigation or settlements can affect competitor launch dates for Keytruda.
The label contains no information about litigation, settlements, or competitor launch dates.
The relevant timeline for Keytruda may be based on patent expiry, supplementary protection timelines, or other exclusivity mechanisms.
The label does not discuss patent expiry, supplementary protection, or other exclusivity mechanisms.
European patent protection for Keytruda is not identical to enforcement in each member state.
The label contains no information about European patent protection or enforcement by member state.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claims do not provide dosing or clinical safety instructions. However, most statements are unsupported by the supplied FDA label and could mislead readers about legally relevant patent or exclusivity timelines.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
The response makes extensive European intellectual-property and market-entry claims that are absent from the supplied FDA label.
Suggested Improvement
Limit label-based content to supported information, such as identifying Keytruda as pembrolizumab and describing the formulation in Section 11. Clearly identify any patent, exclusivity, or European market-entry discussion as outside the scope of the FDA prescribing information.